Contrasting SQZ Biotechnologies (NYSE:SQZ) and Inhibikase Therapeutics (NYSE:IKT)

SQZ Biotechnologies (NYSE:SQZ) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for SQZ Biotechnologies and Inhibikase Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SQZ Biotechnologies	0	0	0	0	0.00
Inhibikase Therapeutics	0	0	4	0	3.00

Inhibikase Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 252.94%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than SQZ Biotechnologies.

Institutional and Insider Ownership

38.5% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

SQZ Biotechnologies has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

Profitability

This table compares SQZ Biotechnologies and Inhibikase Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%
Inhibikase Therapeutics	N/A	-350.63%	-201.82%

Earnings & Valuation

This table compares SQZ Biotechnologies and Inhibikase Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SQZ Biotechnologies	$18.16 million	0.04	-$79.46 million	($2.61)	-0.01
Inhibikase Therapeutics	N/A	N/A	-$19.03 million	($0.39)	-4.36

Inhibikase Therapeutics has lower revenue, but higher earnings than SQZ Biotechnologies. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Summary

SQZ Biotechnologies beats Inhibikase Therapeutics on 7 of the 13 factors compared between the two stocks.

About SQZ Biotechnologies

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.